Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide

Glioblastoma multiforme (GBM) is a CNS (central nervous system) malignancy with a low cure rate. Median time to progression after standard treatment is 7 months and median overall survival is 15 months [1]. Post-treatment vasculogenesis promoted by recruitment of bone marrow derived cells (BMDCs, CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Rios, Adan, Hsu, Sigmund H., Blanco, Angel, Buryanek, Jamie, Day, Arthur L., McGuire, Mary F., Brown, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965258/
https://www.ncbi.nlm.nih.gov/pubmed/27489862
http://dx.doi.org/10.18632/oncoscience.311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965258/
https://www.ncbi.nlm.nih.gov/pubmed/27489862
http://dx.doi.org/10.18632/oncoscience.311

Ejemplares similares